For each new product, Boehringer Ingelheim will pay Enleofen earnout payments of more than US$1 billion ($1.35 billion) in upfront and success-based development and commercialisation milestones.
SINGAPORE (Jan 9): German pharmaceutical giant Boehringer Ingelheim is acquiring assets and intellectual property from Singapore-based biotech company Enleofen Bio, in a step towards finding effective treatments for fibro-inflammatory diseases.
In a press release on Thursday, Enleofen says Boehringer Ingelheim has acquired worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform.
